Pular para o conteúdo principal
Ranking Invest

VIGL - Vigil Neuroscience, Inc.

Segmento: HealthcareVigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.

Análise Ranking Invest

Valuation estimado
-$ 170.74 Mi
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 65.12 Mi

Dívida Líquida

-$ 38.93 Mi

L4T

-$ 86.73 Mi

Indicadores Básicos

ROE

-133.18%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

A0.08

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

G-11.56

Margem

D0.00

Índices de Endividamento

DIV/PAT

-0.60

DIV/L4T

0.45

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.